Holen Sie sich die Stockscreener-App
0.4636
1.34%
0.0044
Geovax Labs Inc Aktie (GOVX) Neueste Nachrichten
GeoVax (NASDAQ: GOVX) plans reverse split after Nasdaq delisting notice - Stock Titan
GeoVax Labs (NASDAQ: GOVX) Secures $3.65M from Warrant Exercise, Issues 11.4M New Warrants at $0.64 - Kalkine Media
GeoVax Labs Inc. Warrants (GOVXW) Key Financial Ratios – Valuation, Profitability & More - Value Research
GeoVax Labs (GOVX) Holds Near $0.72 as Stock Consolidates Within Key Trading RangeInitial Balance - dars.gov.et
GeoVax Raises $3.6M in Warrant Inducement, Issues 11.4M New Warrants - Minichart
GeoVax Raises $3.65M Via Warrant Exercise, Issues 11.4M New Warrants at $0.64 - TradingView
GeoVax Labs Inc. (GOVX) Peer Comparison – Compare with Others - Value Research
GeoVax Labs Inc. (GOVX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
GeoVax Announces a Warrant Inducement Transaction - finance.yahoo.com
GeoVax Advances GEO-MVA Toward Pivotal Phase 3 Study Implementation - finance.yahoo.com
GeoVax Initiates Global Health Outreach to WHO, Africa CDC and Other Agencies Regarding Ebola Vaccine Portfolio Amid Expanding Outbreak - finance.yahoo.com
GeoVax (GOVX) Quarterly Figures: EPS Lands Above Forecast; Post-Report: Shares Close 7.31% Higher in the Latest SessionSlow Growth Warning - vinanet.vn
GOVX Should I Buy - intellectia.ai
Why Is GOVX Stock Falling Today? - Stocktwits
GeoVax Chairman and CEO David Dodd to Participate in 2026 Georgia Life Sciences Summit - Yahoo Finance
GeoVax (GOVX) Financial Results: The Available Earnings Metric Delivers a Beat at the Close; Price Move: Shares Move 0.86% DownRevenue Estimate Trend - vinanet.vn
GOVX Stock Became A Hot Biodefense Trade Amid Ebola, Hantavirus Concerns - Stocktwits
GeoVax Labs (GOVX): Armistice Capital and Steven Boyd disclose 4.99% stake - Stock Titan
GeoVax Labs (GOVX) holders report 1.59% stake tied to 118,715 warrants - Stock Titan
GeoVax Highlights Capabilities Amid Congo's Expanding Ebola Outbreak - Yahoo Finance
GeoVax Labs, Inc. (GOVX) holders cap ownership at 4.99% with warrants - Stock Titan
GOVX: GEO-MVA targets a $1.3B vaccine market gap with expedited approval and scalable U.S. supply - TradingView
GeoVax Labs (GOVX) Dips 3.38% to $0.74, Holding Above Key $0.70 SupportDaily Profile - Vinanet
GeoVax Labs (NASDAQ:GOVX): What Could Today’s program progress and financing needs Update Reveal? - Kalkine Media
GeoVax Labs, Inc. (GOVX) Stock Price, News, Quote & History - Yahoo! Finance Canada
GeoVax targets Q4 phase 3 trial for MVA mpox vaccine with EMA expedited pathway - Proactive financial news
GeoVax Highlights Gedeptin(R) Tumor-Priming Strategy as Immuno-Oncology Enters New Phase - Yahoo Finance
GeoVax Labs (GOVX) Dips 2.07% to $0.75 as Biotech Tests Key SupportConversion Trade - dars.gov.et
Jane Street Group discloses 4.3% GeoVax Labs (GOVX) ownership in updated 13G - Stock Titan
Health preparedness key as biological threats evolve - BioProcess International
GOVX Q2 2026 Earnings: Loss Narrower Than Expected Despite No RevenueBasic EPS Analysis - vinanet.vn
GOVX Q2 2026 Earnings: 66.98% EPS Surprise Lifts Shares 6.75%Post-Earnings Reaction - vinanet.vn
GeoVax Completes Key Milestones for GEO-MVA, Paving Way for Phase 3 Trial - citybuzz -
GeoVax Announces Completion of Key GEO-MVA Development Milestones, Positioning Program for Pivotal Phase 3 Clinical Study - Yahoo Finance
GeoVax Highlights Newly Published Independent Research Supporting Broader Filovirus Vaccine Strategies and Strategic Value of Its MVA-Based Vaccine Portfolio - Yahoo Finance
GeoVax Labs (GOVX) Q2 2026 Earnings: Narrower-Than-Expected Loss of -$0.97 Per ShareOne-Time Loss Impact - vinanet.vn
GeoVax Labs Inc (GOVX) Institutional Confidence - TradingKey
GOVX Q2 2026 Earnings: EPS Surprises Positively Despite Revenue AbsenceReturn On Assets - vinanet.vn
GOVX Q2 2026 Earnings: Narrower-than-expected loss highlights cost discipline amid developmental stageRevenue Inflection Point - vinanet.vn
GeoVax Labs (GOVX) Drops 6.82% as Biotech Stock Tests Key Support LevelsTurnaround Stocks - dars.gov.et
GeoVax Labs Inc (GOVX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Geovax Labs Market Sentiment - es.benzinga.com
GeoVax Labs, Inc. 2026 Q2 Financial Report: Earnings, Losses & Key Financial Statements Overview - Minichart
GeoVax Advances GEO-MVA Pivotal Study Amid Strategic Reprioritization - citybuzz -
GeoVax Labs, Inc. Reports Q2 2026 Financial Results and Advances in Immuno-Oncology Programs - Minichart
GEOVAX LABS ($GOVX) Releases Q2 2026 Earnings - Quiver Quantitative
GeoVax Labs Inc reports results for the quarter ended June 30Earnings Summary - TradingView
GeoVax Reports Q2 2026 Net Loss of $4.4 Million - Quiver Quantitative
GeoVax Labs reports Q2 net loss $4.43M, cash ~$3.1M; advances GEO‑MVA pivotal study - TradingView
GeoVax Labs, Inc. 2026: Revenue $0 EPS ($0.97) — 10-Q Summary - TradingView
GeoVax Labs (GOVX) narrows loss but warns on cash runway and Nasdaq risk - Stock Titan
GeoVax Reports Second Quarter 2026 Financial Results and Provides Business Update - TradingView
GeoVax Labs Inc (GOVX) Cash Flow - TradingKey
GeoVax Labs Inc (GOVX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GeoVax Labs Inc (GOVX) Balance Sheet - TradingKey
GeoVax Labs Inc (GOVX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GOVX Q1 2026 Earnings: Narrowed Loss Beats Estimates Amid No RevenueQuarterly Financial Update - vinanet.vn
GeoVax Labs, Inc. Revenue Breakdown – NASDAQ:GOVX - TradingView
GeoVax Labs Inc (GOVX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GeoVax Labs (GOVX) Tumbles 13% as Biotech Stock Tests Key Support at $0.69Earnings Breakout Stocks - dars.gov.et
GOVX|GeoVax Labs Inc|Price:0.755|Chg%:+0.024 - TradingKey
GOVX|GeoVax Labs Inc|Price:0.770|Chg%:+0.049 - TradingKey
GeoVax Labs Inc (GOVX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GeoVax Labs Inc (GOVX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
0.28%
4.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):